Suppr超能文献

来自人类白细胞抗原(HLA)匹配的无关供体的减低强度造血干细胞移植的可行性

Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.

作者信息

Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, Kojima R, Kishi Y, Kim S-W, Ueyama J, Miyakoshi S, Tanosaki R, Morinaga S, Mori S, Heike Y, Muto Y, Masuo S, Taniguchi S, Takaue Y

机构信息

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

出版信息

Bone Marrow Transplant. 2004 Apr;33(7):697-702. doi: 10.1038/sj.bmt.1704425.

Abstract

To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m(2), n=18) or cladribine-based (0.77 mg/kg, n=2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P=0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.

摘要

为评估采用匹配无关供者(MUD)骨髓进行减低强度干细胞移植(RIST)的可行性,我们回顾性研究了2000年1月至2002年10月在东京干细胞移植联盟接受RIST的20例血液系统疾病患者。预处理方案以氟达拉滨为主(150 - 180 mg/m²,n = 18)或以克拉屈滨为主(0.77 mg/kg,n = 2)。为提高植入率,分别在9例和11例患者的这些方案中加入了抗胸腺细胞球蛋白(ATG)和4或8 Gy全身照射(TBI)。移植物抗宿主病(GVHD)预防采用环孢素,加或不加甲氨蝶呤。总共19例实现了初次植入。3例发生移植失败(1例原发性,2例继发性),5例在移植后100天内死于治疗相关死亡率。19例实现初次植入的患者中有7例发生了Ⅱ - Ⅳ级急性GVHD,13例存活超过100天的患者中有7例发生了慢性GVHD。中位随访5.5个月时,估计1年总生存率为35%。与含TBI的方案相比,含ATG的方案移植失败风险较高(30%对0%,P = 0.0737)。本研究支持了来自MUD的RIST的可行性;然而,在将其应用于患者时,与操作相关的毒性仍然很显著。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验